243 related articles for article (PubMed ID: 32959046)
1. CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies.
Le Cann M; Bouhour F; Viala K; Simon L; Tard C; Rossi C; Morel G; Lagrange E; Magy L; Créange A; Michaud M; Franques J; Echaniz-Laguna A; Antoine JC; Baron M; Arnulf B; Puma A; Delmont E; Maisonobe T; Leblond V; Roos-Weil D
Blood; 2020 Nov; 136(21):2428-2436. PubMed ID: 32959046
[TBL] [Abstract][Full Text] [Related]
2. [Identification and characterization of a monoclonal IgM reacting with disialylated gangliosides recognizing the CANOMAD syndrome].
Boussaïd I; Bouhour F; Vial C; Caudie C
Ann Biol Clin (Paris); 2011; 69(4):476-80. PubMed ID: 21896416
[TBL] [Abstract][Full Text] [Related]
3. [A syndrome of chronic ataxic polyneuropathy, ophtalmoplegia, IgM paraprotein, cold agglutinins and anti-disialosyl antibodies can cause diplopia in patients with chronic sensory polyneuropathy].
Kolmos EB; Moth Henriksen M; Abildgaard N; Sindrup SH
Ugeskr Laeger; 2012 Oct; 174(43):2635-6. PubMed ID: 23095653
[TBL] [Abstract][Full Text] [Related]
4. Chronic ataxic neuropathy mimicking dorsal midbrain syndrome.
Arbogast SD; Khanna S; Koontz DW; Tomsak RL; Katirji B; Leigh RJ
J Neurol Neurosurg Psychiatry; 2007 Nov; 78(11):1276-7. PubMed ID: 17504882
[TBL] [Abstract][Full Text] [Related]
5. Relapsing sensorimotor neuropathy with ophthalmoplegia, antidisialosyl antibodies, and extramembranous glomerulonephritis.
Delval A; Stojkovic T; Vermersch P
Muscle Nerve; 2006 Feb; 33(2):274-7. PubMed ID: 16258949
[TBL] [Abstract][Full Text] [Related]
6. CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA).
Garcia-Santibanez R; Zaidman CM; Sommerville RB; Lopate G; Weihl CC; Pestronk A; Bucelli RC
J Neurol; 2018 Jun; 265(6):1402-1409. PubMed ID: 29633012
[TBL] [Abstract][Full Text] [Related]
7. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies.
Willison HJ; O'Leary CP; Veitch J; Blumhardt LD; Busby M; Donaghy M; Fuhr P; Ford H; Hahn A; Renaud S; Katifi HA; Ponsford S; Reuber M; Steck A; Sutton I; Schady W; Thomas PK; Thompson AJ; Vallat JM; Winer J
Brain; 2001 Oct; 124(Pt 10):1968-77. PubMed ID: 11571215
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Rituximab in CANOMAD: A Systematic Review.
Aguirre AS; Vivanco RA; Ortiz JF; Rozen V; InsuastI WE; Fiallos J; Gallegos C; Villavicencio A; Salazar K; Duenas F; Singla R
Cureus; 2023 May; 15(5):e39237. PubMed ID: 37337500
[TBL] [Abstract][Full Text] [Related]
9. [Ataxic neuropathy associated with disialosylated antibodies: description of new clinical and biochemical forms].
Delval A; Stojkovic T; de Sèze J; Hurtevent JF; Glowacki F; Beaume A; Destée A; Vermersch P
Rev Neurol (Paris); 2004 Oct; 160(10):910-6. PubMed ID: 15492717
[TBL] [Abstract][Full Text] [Related]
10. Canomad presenting without ophthalmoplegia and responding to intravenous immunoglobulin.
Kam C; Balaratnam MS; Purves A; Mills KR; Riordan-Eva P; Pollock S; Bodi I; Munro NA; Bennett DL
Muscle Nerve; 2011 Nov; 44(5):829-33. PubMed ID: 22006700
[TBL] [Abstract][Full Text] [Related]
11. CANOMAD syndrome with respiratory failure.
Salamon A; Dézsi L; Radics B; Varga ET; Hortobágyi T; Tömösvári A; Vécsei L; Klivényi P; Rajda C
Ideggyogy Sz; 2020 Mar; 73(3-4):141-144. PubMed ID: 32364342
[TBL] [Abstract][Full Text] [Related]
12. Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients.
Chauvet S; Bridoux F; Ecotière L; Javaugue V; Sirac C; Arnulf B; Thierry A; Quellard N; Milin S; Bender S; Goujon JM; Jaccard A; Fermand JP; Touchard G
Am J Kidney Dis; 2015 Nov; 66(5):756-67. PubMed ID: 25987261
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.
Lunn MP; Nobile-Orazio E
Cochrane Database Syst Rev; 2012 May; (5):CD002827. PubMed ID: 22592686
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of CANOMAD with IVIg and rituximab.
Löscher WN; Woertz A; Wallnöfer M; Wanschitz JV; Luef G
J Neurol; 2013 Apr; 260(4):1168-70. PubMed ID: 23400502
[No Abstract] [Full Text] [Related]
15. IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy.
Campagnolo M; Zambello R; Nobile-Orazio E; Benedetti L; Marfia GA; Riva N; Castellani F; Bianco M; Salvalaggio A; Garnero M; Ruiz M; Mataluni G; Fazio R; Ermani M; Briani C
J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1094-1097. PubMed ID: 28501820
[No Abstract] [Full Text] [Related]
16. Canomad: report of a case with a 40-year history and autopsy. Is this a sensory ganglionopathy with neuromuscular junction blockade?
McKelvie PA; Gates PC; Day T
Muscle Nerve; 2013 Oct; 48(4):599-603. PubMed ID: 23649749
[TBL] [Abstract][Full Text] [Related]
17. Treatment of immune-mediated, dysimmune neuropathies.
Finsterer J
Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
[TBL] [Abstract][Full Text] [Related]
18. Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy.
Attarian S; Boucraut J; Hubert AM; Uzenot D; Delmont E; Verschueren A; Franques J; Azulay JP; Pouget J
J Neurol Neurosurg Psychiatry; 2010 Jan; 81(1):61-4. PubMed ID: 19726417
[TBL] [Abstract][Full Text] [Related]
19. Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy.
Stork AC; Jacobs BC; Tio-Gillen AP; Eurelings M; Jansen MD; van den Berg LH; Notermans NC; van der Pol WL
J Neuroimmunol; 2014 Mar; 268(1-2):89-94. PubMed ID: 24529728
[TBL] [Abstract][Full Text] [Related]
20. [Chronic sensory ataxic neuropathy associated with IgM antibody against b-series gangliosides including GD1b].
Susuki K; Koga M; Yuki N; Johkura K; Kuroiwa Y
Rinsho Shinkeigaku; 1999 Sep; 39(9):967-70. PubMed ID: 10614164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
